CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 197 enrolled
Drug / intervention
10 µg/day E2 with NES 200® µg/day +2 moredrug
Likely dose
10 µg/day E2 with NES 200® µg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01586000
NCT01586000Phase 2Completed
CompareCT.gov

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

Kimberly Myer·interventional·Posted Apr 26, 2012·Updated Dec 8, 2025

In Brief

A Phase 2 clinical trial evaluating 10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, and 1 other intervention for Suppression of Ovulation. Completed, enrolled 197 participants across 8 sites.

Detailed Summary

This clinical trial is an experimental research study using a potential new form of birth control. Clinical trials include people who volunteer to take part in a study. Take your time to decide if you want to be part of this experimental research study. If you want to know more about this study first, ask the study doctor or study site staff. The investigators can also give you the study information written for doctors and clinic staff.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSuppression of Ovulation
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Population Council

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 26, 2012
Enrollment StartMar 1, 2012
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.2 years ago

Interventions

10 µg/day E2 with NES 200® µg/daydrug

10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)

20 µg/day E2 with NES 200® µg/daydrug

20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)

40 µg/day E2 with NES 200® µg/daydrug

40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)